Triglav Skladi D.O.O. Purchases Shares of 16,200 Cencora, Inc. (NYSE:COR)

Triglav Skladi D.O.O. bought a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 16,200 shares of the company's stock, valued at approximately $3,640,000.

Other institutional investors also recently bought and sold shares of the company. JFS Wealth Advisors LLC boosted its stake in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA purchased a new position in shares of Cencora in the fourth quarter worth $29,000. SBI Securities Co. Ltd. purchased a new position in shares of Cencora in the fourth quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC raised its holdings in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after buying an additional 69 shares during the last quarter. Finally, Kentucky Trust Co purchased a new position in shares of Cencora in the fourth quarter worth $33,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,223 shares of company stock worth $13,580,967. Company insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on COR shares. Morgan Stanley set a $288.00 price objective on shares of Cencora in a research note on Tuesday, April 15th. Citigroup lifted their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. UBS Group boosted their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Robert W. Baird boosted their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Finally, Wells Fargo & Company lifted their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average target price of $301.18.

Cencora Stock Down 0.5%

NYSE COR traded down $1.33 on Thursday, hitting $290.03. 1,057,854 shares of the stock were exchanged, compared to its average volume of 1,545,015. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $309.35. The company has a market cap of $56.21 billion, a PE ratio of 41.26, a PEG ratio of 1.31 and a beta of 0.60. The company has a 50-day moving average price of $281.86 and a 200-day moving average price of $256.65.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the prior year, the business posted $3.80 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. The ex-dividend date is Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.